U.S. FDA grants interchangeability designation to Celltrion’s denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
The U.S. FDA approved STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangeable with the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications, effective as of October 29, 2025 The interchangeability (IC) designations of STOBOCLO and OSENVELT were granted based not only on the comparative clinical data – including pharmacokinetics, efficacy, safety and an...
United Imaging Healthcare Q3 2025 Results: In The First Three Quarters Of 2025, Overseas Revenue Up 42% YoY
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- United Imaging Healthcare (SSE: 688271), a global leader in advanced medical imaging and radiotherapy equipment, has released its financial results for the first three quarters of 2025, showcasing robust financial performance. During this period, the company's revenue and net profit attributable to ordinary shareholders after deducting non-recurring profit, reached CNY 8.86 billion and...
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders
Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries. Under the assigned exclusive license, Everest Medicines will make an upfront payment of US$7 million (equivalent to approximately RMB49.7 million) and reimburse up to RMB24.0 million for prior expenses; and pay up to US$89.0 million...
LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities
Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market. The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported by joint marketing based on deep ADC expertise. SEOUL, South Korea, Oct. 30, 2025 /PRNewswire/...
Jenscare released its multi-product portfolio’s, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S.
BEIJING, Oct. 30, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 6-month follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes and challenging cases of JensClip and Ken-Valve, a proprietary TMVr system and TAVR (AR) system respectively, representing the...
ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Monoclonal Antibody for Respiratory Syncytial Virus Infection
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. Building on ArkBio's previous experience and knowledge in development of RSV therapeutics, this milestone marks...
Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development
-In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in humans. -ASC36 demonstrated approximately 91% greater relative body weight reduction compared to petrelintide in a head-to-head diet-induced obese (DIO) rat study. -ASC36 has excellent chemical and physical stability with no...
Jungbunzlauer Tricalcium Citrate Excipient Demonstrates Outstanding Results in Direct Compression Study
- New research confirms Jungbunzlauer's TCC TB supports efficient, high-quality tablet manufacturing across challenging pharmaceutical and nutraceutical applications - BASEL, Switzerland, Oct. 29, 2025 /PRNewswire/ -- Jungbunzlauer, a global leader in high-quality, sustainable ingredients, and Professor Karl Wagner from the University of Bonn, announce the results of new research confirming Jungbunzlauer's tricalcium...
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide Strategy centers on broadening access to global capital and innovation through a planned Hong Kong initial public offering (IPO), and holding dual listings on Nasdaq and Hong Kong Stock Exchange (HKEX) Consistent with...
Suvoda launches unified patient app to reduce logistical challenges for clinical trial participants
CONSHOHOCKEN, Pa., Oct. 29, 2025 /PRNewswire/ -- Suvoda (recently merged under common ownership with Greenphire), a global clinical trial technology company specializing in software solutions to address trial complexity in mission-critical, time-sensitive moments, today announced the release of its unified patient mobile app. The Suvoda app is a single, intuitive experience that will bring...
